DUBLIN, August 12, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Bispecific Antibody Market & Clinical Pipeline Insight 2020" drug pipelines to their offering.

The pipeline of bispecific antibodies seems to be extremely rich with more than 100 proposed drugs in trials with most of them being in their Preclinical trials. Most of these drugs are propagated to enter the market in the coming 5 to 6 years, occupying a huge segment of health market. The phase is stipulated to swirl the medical world as this will for sure lead to more investments in this direction. The major challenges associated are the monetary restrictions for both the manufacturers as well as the consumers.

Everything novel in medical sector comes with a huge price tag and this was proved by extensively costly therapy of Blinatumomab, which costed $178,000 per two-cycles making it unachievable for the common patients. Other associated challenges include stringent regulatory guidelines, conduction of clinical trials and long duration of research associated.

This report extensively covers the major events from the infancy to the present status of the Bispecific antibodies. It gives a purposeful outlook of the bright future of this wonder molecule which is sure to establish its niche in the coming years; as the abnormalities it is proposed to deal with along with the ways to mitigate them is proportionately too high to be ignored.

Global Bispecific Antibody Market & Clinical Pipeline Insight 2020 Report Highlights:

- Overview of Bispecific Antibody

- Mechanism of Action of Bispecific Antibody

- Design & Engineering of Bispecific Antibodies

- Applications of Bispecific Antibodies

- Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

- Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies

- Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)

Key Topics Covered:

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism of Action of Bispecific Antibody

3.1 Trifunctional Antibody: Catumaxomab (Removab®)

3.2 Blinatumomab

4. The Design & Engineering of Bispecific Antibodies

4.1 The Design & Engineering of IgG like Bispecific Antibodies

4.1.1 Quadroma (Hybrid Hydromas) Approach

4.1.2 Knobs Into Holes Approach

4.1.3 CrossMab Approach

4.1.4 Dual-Variable-Domain Immunoglobulin Approach

4.2 Small Bispecific Antibodies

4.2.1 Bispecific Diabodies

4.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

5. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

6. Applications of Bispecific Antibodies

6.1 BsMAb for Diagnosis of Infectious Diseases

6.1.1 Diagnosis of Bacterial Infections

6.1.2 Diagnosis of Viral Infections

6.2 BsMAb for Cancer Diagnostic

6.3 BsAbs Blocking Signaling Pathways

6.4 BsAbs Targeting Tumor Angiogenesis

6.5 Specific Delivery of Effector Compounds to Targets

6.6 Bispecific Antibodies & Gene Therapy

7. Global Bispecific Antibody Market Overview

7.1 Current Market Scenario

7.1.1 Catumaxomab (Removab)

7.1.2 Blinatumomab

7.1.3 Duligotumab

7.1.4 SAR 156597

7.2 Global Bispecific Antibodies Clinical Pipeline Overview

8. Global Bispecific Antibody Market Dynamics

8.1 Favorable Market Parameters

8.1.1 Target Patient Base

8.1.2 Severity Of The Disease

8.1.3 Unavailability Of Completely Curing Drugs

8.1.4 Side Effects of the Existing Drugs

8.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells

8.2 Commercialization Challenges

8.2.1 Stringent Regulatory Guidelines

8.2.2 Long Duration of Research & Development

8.2.3 Clinical Trial Timeline

8.2.4 High Cost for Research & Development

9. Global Bispecific Antibody Market Future Prospects

10. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-III

11. Marketed Bispecific Antibodies Clinical Insight

11.1 Blinatumomab (Blincyto)

11.2 Catumaxomab (Removab)

12. Discontinued & Suspended Bispecific Antibodies in Clinical Pipeline by Company, Indication & Phase

12.1 Discontinued

12.2 No Development Reported

13. Competitive Landscape

13.1 Ablynx

13.2 Adimab

13.3 Affimed Therapeutics

13.4 Amgen

13.5 AstraZeneca (MedImmune)

13.6 Chugai Pharmaceutical

13.7 Eli Lilly

13.8 EMD Serono

13.9 Emergent BioSolutions

13.10 Genentech

13.11 Genmab

13.12 Immunomedics

13.13 Jounce Therapeutics

13.14 MacroGenics

13.15 Merus

13.16 Neovii Biotech

13.17 NovImmune SA

13.18 OncoMed Pharmaceuticals

13.19 Pieris

13.20 Regeneron Pharmaceuticals

13.21 Roche

13.22 Sanofi

For more information visit http://www.researchandmarkets.com/research/758qpr/global_bispecific

Media Contact:

Laura Wood, Senior Manager

press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets